(Q44593368)

4 December 2017

title

Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis (English)

1 reference

4 December 2017

0 references

Matthias Jürgens

1

1 reference

4 December 2017

Rüdiger P Laubender

2

1 reference

4 December 2017

Franziska Hartl

3

1 reference

4 December 2017

Maria Weidinger

4

1 reference

4 December 2017

Julia Seiderer

5

1 reference

4 December 2017

Johanna Wagner

6

1 reference

4 December 2017

Martin Wetzke

7

1 reference

4 December 2017

Florian Beigel

8

1 reference

4 December 2017

Simone Pfennig

9

1 reference

4 December 2017

Johannes Stallhofer

10

1 reference

4 December 2017

Fabian Schnitzler

11

1 reference

4 December 2017

Cornelia Tillack

12

1 reference

4 December 2017

Peter Lohse

13

1 reference

4 December 2017

Burkhard Göke

14

1 reference

4 December 2017

Jürgen Glas

15

1 reference

4 December 2017

Thomas Ochsenkühn

16

1 reference

4 December 2017

Stephan Brand

17

1 reference

4 December 2017

language of work or name

English

0 references

publication date

2 March 2010

1 reference

The American Journal of Gastroenterology

4 December 2017

published in

1 reference

4 December 2017

volume

105

1 reference

4 December 2017

issue

8

1 reference

4 December 2017

page(s)

1811-1819

1 reference

Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

Increased expression of interleukin 17 in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

The role of the novel Th17 cytokine IL-26 in intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

The immunological and genetic basis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

Predictors of early response to infliximab in patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

rs1004819 is the main disease-associated IL23R variant in German Crohn's disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

Evidence for association of an interleukin 23 receptor variant independent of the R381Q variant with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

Essential autocrine regulation by IL-21 in the generation of inflammatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

Long-term outcome after infliximab for refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

Colectomy rate in acute severe ulcerative colitis in the infliximab era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.95

21 January 2018

Identifiers

DOI

10.1038/AJG.2010.95

1 reference

4 December 2017

1 reference